Boehringer Ingelheim

For Healthcare Professionals

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Therapeutic Area
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.

Section Overview

Therapeutic Area

Section Overview

Cardiovascular

Metabolic

Inflammation

Respiratory
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

See all products

Products

See all products
Resources
Contact
Logout

Boehringer Ingelheim

Expert's Video
Prescribing Information
Jardiance HF

banner-heartfailure-desktop

Empagliflozin's Proven Efficacy and safety in HF patients with or without T2D

27/03/2023 | Document ID: PC-PH-104581

PTPHF||JRDHF||Let's Talk - Impact of SGLT2i trials in HFpEF

PTPHF||JRDHF||Let's Talk - Guidelines HFrEF

Initiating Empagliflozin in HF patients with low eGFR

Empagliflozin JARDIANCE improves QoL of HF patients

Empagliflozin has consistent CV benefits in the full spectrum of HF

Empagliflozin's robust renal data in the full spectrum of HF

JRDHF||Empagliflozin's Proven Efficacy and safety in HF patients with or without T2D

JRDHF||Renal efficacy and safety of Empagliflozin in HF

JRDHF||How confident are you to start Empagliflozin to non-T2D HF patients?

JRDHF||How effective is Empagliflozin with or without ARNI?

RELATED CONTENT

JRDHF||Empagliflozin's robust renal data in the full spectrum of HF

1:47

JRDHF||Empagliflozin's robust renal data in the full spectrum of HF

Watch now Opens in new tab

JRDHF||Empagliflozin has consistent CV benefits in the full spectrum of HF

2:29

JRDHF||Empagliflozin has consistent CV benefits in the full spectrum of HF

Watch now Opens in new tab

JRDHF||Empagliflozin JARDIANCE improves QoL of HF patients

3:42

JRDHF||Empagliflozin JARDIANCE improves QoL of HF patients

Watch now Opens in new tab

JRDHF||Early initiation of Empagliflozin in the full spectrum of HF

3:23

JRDHF||Early initiation of Empagliflozin in the full spectrum of HF

Watch now Opens in new tab

JRDHF||Initiating Empagliflozin in HF patients with low eGFR

2:09

JRDHF||Initiating Empagliflozin in HF patients with low eGFR

Watch now Opens in new tab

Production Date: March 2023

Home
Metabolic
Empagliflozin
Expert's video
JRDHF||Empagliflozin's Proven Efficacy and safety in HF patients with or without T2D

Sitemap

Therapeutic Area

Resources
- Videos
- Clinical studies

BI logo

Privacy
Terms of use
Sitemap
Contact

Copyright © 2025 Boehringer Ingelheim (Philippines), Inc. All rights reserved. Use of this Site is subject to the Terms of Use and Privacy Statement. Prepared June 2025